Post-marketing data on CGRP inhibitors show paucity of data and additional risks from chronic biologic use

This narrative review focuses on monoclonal antibodies and Calcitonin Gene-Related Peptide (CGRP) inhibitors used to treat migraine. The publication is a review rather than a primary trial, and it addresses the post-marketing phase of these medications. The authors synthesize the current state of knowledge by pointing out a paucity of data available for these agents. They specifically mention the limitations of pre-marketing experience as a significant gap in understanding these therapies. The review also discusses additional risks associated with the intrinsic characteristics of biologic compounds in general. Furthermore, the authors emphasize the issue of chronic use of most of these drugs as a concern. The text does not report specific adverse events, serious adverse events, discontinuations, or tolerability rates because these details were not reported in the source. The review acknowledges that active pharmacovigilance carried out during the post-marketing phase aims to fill gaps by using continuous and pre-organized processes to fully identify the number of adverse events. This ongoing surveillance is intended to address the current lack of comprehensive safety information. The practice relevance is framed around the need for continued monitoring rather than established efficacy or safety profiles. Clinicians should be aware that the evidence base remains incomplete for these specific migraine treatments.